Analysis on Proportion and Development of Steel Workers’ Hospitalization Costs

2011 ◽  
Vol 84-85 ◽  
pp. 715-719
Author(s):  
Su Feng Yin ◽  
Sha Li ◽  
Ying Zhao ◽  
Xiao Jing Wang ◽  
Jian Hui Wu
Keyword(s):  
Blood Transfusion ◽  
Laboratory Tests ◽  
Medical Costs ◽  
Steel Worker ◽  
Development Trends ◽  
Steel Workers ◽  
Hospitalization Costs ◽  
Dynamic Series ◽  
Observation Period

In order to understand the distribution of hospitalization costs and development trends in Steel worker hospital, we used the proportion, the dynamic series and other indicators to analyze the Proportion and the developments of all medical costs spent by inpatients in a hospital during 2002 to 2009. As a result, expenditure on medicine obtained the largest proportion of the hospitalization costs. In the observation period, the proportion of medicine and laboratory tests kept growing, particularly of the medicine costs. While the blood transfusion costs decreased. The results indicated that we should focus on medicine costs firstly and then on laboratory tests fees to control the growth of hospitalization costs of steel workers.

scholarly journals Cost analysis of staged versus simultaneous bilateral total knee and hip arthroplasty using a propensity score matching

BMJ Open ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. e041147
Author(s):  
Ji-Fei Hou ◽  
Chuan Hu ◽  
Yun Zhang ◽  
Li-Qi Tian ◽  
Yan-Zheng Liu ◽  
...  
Keyword(s):  
Blood Transfusion ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Nursing Care ◽  
Hip Arthroplasty ◽  
Medical Costs ◽  
Complication Rates ◽  
Propensity Score Matching Analysis ◽  
Total Knee ◽  
The Difference

BackgroundTotal joint arthroplasty (TJA), including total knee arthroplasty (TKA) and total hip arthroplasty (THA), is required for many patients. This study aimed to evaluate the medical costs, length of stay (LOS), blood transfusion and in-hospital complications in patients undergoing simultaneous and staged TJA.MethodsAll patients who underwent primary bilateral TJA from 2013 to 2018 in our institute were included. The propensity score matching analysis was performed between simultaneous and staged TJA patients. The difference in medical costs, LOS, blood transfusion and in-hospital complications was compared between simultaneous and staged groups.ResultsExcept for materials fees and general therapy fees, medical costs (bed fees, general therapy fees, nursing care fees, check-up and laboratory test fees, surgical fees and drug fees) were significantly lower in the simultaneous TKA, THA and TJA group. The total average medical costs in simultaneous and staged TKA groups were $15 385 and $16 729 (p<0.001), respectively; THA groups were $14 503 and $16 142 (p=0.016), respectively; TJA groups were $15 389 and $16 830 (p<0.001), respectively. The highest and lowest costs were materials fees and nursing care fees. No significant differences were found for five common comorbidities and postoperative complications between the two subgroups. The simultaneous groups had a shorter LOS and the differences from the staged group for TKA, THA and the TJA group were 8, 6 and 8 days, respectively. The incidence of blood transfusion is higher for simultaneous groups and the difference from the staged group for TKA, THA and TJA is 32.69%, 18% and 29.3%, respectively.ConclusionsOur results indicate that simultaneous TKA and THA with a shorter LOS would cost fewer (costs incurred during hospitalisation) than staged TKA and THA. Complication rates were not affected by the choice for staged or simultaneous arthroplasty, but the incidence of blood transfusion was higher in the simultaneous groups.

SALMONELLA BREDENEY MENINGITIS

PEDIATRICS ◽  
1952 ◽  
Vol 9 (5) ◽  
pp. 597-601
Author(s):  
HOWARD L. KANTOR
Keyword(s):  
Blood Transfusion ◽  
Carrier State ◽  
Careful Examination ◽  
Rapid Improvement ◽  
Clinical Recovery ◽  
Source Of Infection ◽  
The Family ◽  
Salmonella Meningitis ◽  
Observation Period ◽  
Multiple Antibiotics

A case of Salmonella bredeney meningitis with recovery in a 19 day old infant is reported. This is the youngest patient with Salmonella meningitis known to have recovered. This is the second known case of Salmonella meningitis with recovery in a patient less than one month of age. Treatment with multiple antibiotics and chemotherapy both parenterally and intrathecally produced rapid improvement. An equally effective supportive blood transfusion may have aided this recovery. The use of chloromycetin after discontinuance of all other antibiotics was effective in producing a clinical recovery without relapse. No sequelae were noted at the end of a three month observation period. Attempts at discovering the carrier state of the infesting organism by careful examination of the family revealed no source of infection.

scholarly journals Annual Prevalence, Health Expenditures, and Co-Morbidities Trend of Iron Deficiency Anemia in Korea: National Health Insurance Service Data from 2002 to 2013

2020 ◽  
Vol 17 (12) ◽  
pp. 4433
Author(s):  
Yoo-Jin Park ◽  
Hee-Sook Lim ◽  
Tae-Hee Kim
Keyword(s):  
Iron Deficiency ◽  
Nutritional Status ◽  
Iron Deficiency Anemia ◽  
National Health ◽  
Health Expenditures ◽  
Medical Costs ◽  
Deficiency Anemia ◽  
Prevalence Rates ◽  
Annual Prevalence ◽  
Hospitalization Costs

Despite improvements in nutritional status, iron deficiency anemia (IDA) remains a debilitating nutritional problem worldwide. We estimate annual IDA prevalence rates by sex and age and the trends therein in Korea. We also calculate the health expenditures of IDA and its co-morbidities by analyzing claims data in the National Health Information Database from 2002 to 2013. All analyses were performed based on diagnosis codes of IDA (D50, D50.0, D50.8, and D50.9) regardless of whether IDA was the principal or a coexisting disease. Trends in IDA prevalence rates were evaluated by calculating annual percent changes (APCs) in prevalence. The health expenditures of IDA were calculated based on the direct medical costs (outpatient and hospitalization costs, pharmaceutical costs) and direct non-medical costs (travel costs). The overall IDA prevalence in both sexes increased approximately 2.3-fold from 2002 to 2013; the APC was +7.6%. In females, the prevalence of IDA was highest in aged 30–39 and 40–49 years. The APC was highest in those aged <10 years (+18.2%), followed by those aged ≥80 (+14.7%) and 70–79 (+9.8%) years. In males, the prevalence rates were highest in aged <10 years, followed by those aged ≥60 years. The APC was highest in those aged <10 years (+19.1%), followed by those aged ≥80 years (+10.5%). The total health expenditures increased 2.8-fold during 12 years. Diseases of the respiratory or gastrointestinal tract were the most prevalent co-morbidities in both males and females. The annual prevalence of IDA continues to rise in association with adverse health expenditures and co-morbidities in spite of improvements in nutritional status. Most importantly, infants and young children, the elderly, and females aged 30–49 years are at highest risk of IDA. A national, prospective, and well-organized effort to improve iron status and to manage IDA is required.

Treatment Persistence with Azacitdine (Vidaza) Is Associated with Lower Inpatient Hospitalization Costs Over Time

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4231-4231
Author(s):  
B. Douglas Smith ◽  
Dalia Mahmoud ◽  
Stacey Dacosta Byfield ◽  
Henry J Henk
Keyword(s):  
Health Care ◽  
Health Care Costs ◽  
Medical Costs ◽  
Sensitivity Analyses ◽  
Bleeding Complications ◽  
Inpatient Hospitalization ◽  
Treatment Persistence ◽  
Hospitalization Costs ◽  
The Relationship ◽  
Care Costs

Abstract Abstract 4231 Background: In the US, understanding the costs associated with Myelodysplastic Syndromes (MDS) is challenging given that multiple channels including pharmacy, ambulatory, and inpatient hospitalization (IPH) settings make up the total expenses to manage patients. Recent studies suggest that MDS patients under active medical management experience fewer cytopenia-related medical problems compared to untreated, transfusion dependent (TD) patients who require more medical treatments, often for recurrent infections and bleeding complications. It is clear that persistence of drug therapy is essential to achieve optimal clinical responses for MDS patients and we sought to determine if continued therapy also optimized costs related to the disease. Aim: To evaluate the relationship between treatment persistence with AZA and health care costs encountered for patients with MDS. Methods: Commercial and Medicare Advantage enrollees with a diagnosis of high grade MDS (ICD-9, 238.73) who initiated AZA with pharmacy and medical benefits in the prior 6 months and who had a variable follow up period from initiation of AZA to disenrollment or end of study were identified in a US health plan claims database (1/1/2007-6/30/2010). The number of AZA “cycles” was calculated by dividing the total number of AZA administrations by 7 days, with a sensitivity analysis for 5 day administration, - commonly utilized in the “real-world”. Persistence was defined as the number of cycles of AZA. Eligible patientshad to have at least 2 AZA cycles. An independent analysis identified health care costs for the same patients during periods of transfusion-dependence (TD) - defined as periods in which they received 2 transfusions in an 8 week period and did not receive erythropoietin-stimulating agents (ESAs) or AZA. Average Per Patient Per Month (PPPM) costs were examined among patients with various lengths of TD periods, up to 1 year. Linear models were used to examine the relationship between persistence on AZA and PPPM health care costs. Healthcare costs included both payer and patient paid amounts under the medical and pharmacy benefit. Medical costs were further broken out into IPHs, ambulatory, and other costs captured. Several sensitivity analyses were performed to confirm the robustness of the results such as excluding patients with IPH prior to AZA initiation, and including patients with <2 cycles of AZA. Results: The baseline cost breakdown for MDS patients (n=225) who were transfusion dependent and not receiving treatment are outlined in Figure 1. Interestingly, the largest proportion of the medical costs for TD patients comes from IPHs. In fact, the PPPM IPH costs among TD periods account for approximately 65–75% of total health care costs - even at one year of their diagnosis. A similar analysis was done for patients completing at least 2 cycles of AZA (n = 100) which suggested that the proportion of cost related to IPHs was closer to 40%. This cohort averaged 6.3 cycles (median = 5) with 24% of patients completing at least 8 cycles. Importantly, completion of every additional AZA cycle (baseline 7day analysis) was found to be associated with, on average, a 6% decrease in medical care costs (p=0.005) driven largely by an 18% decrease in IPH costs (p<0.001; Figure 2) due to fewer medical events. Even a single additional AZA cycle was found to be associated with 5% lower total health care cost (p=0.006). These results also hold in the sensitivity analyses. As expected, an examination of medical needs of both TD and AZA treated patients led infections as a frequent driver of IPHs. Conclusions: Patients who persist with AZA therapy have lower PPPM medical costs, driven by decreased expenditures on IPHs. This is consistent with results identified in the AZA-001 clinical trial in which patients receiving AZA experienced reduced IPHs driven by less transfusions and need for IV antibiotics, antifungals, and antivirals. These lower overall costs offset the expected increase in continuing therapy based on the cost of drug alone. Improving duration of therapy of AZA may not only optimize clinical outcomes but may decrease cumulative costs of care among high risk MDS patients. Disclosures: Smith: Celgene: Consultancy. Mahmoud:celgene: Employment. Dacosta Byfield:Celgene: Consultancy. Henk:Celgene: Consultancy.

scholarly journals Perioperative Complications of Laminoplasty in Degenerative Cervical Myelopathy -A Comparative Study Between Ossification of Posterior Longitudinal Ligament and Cervical Spondylotic Myelopathy Using a Nationwide Inpatient Database

2021 ◽  
pp. 219256822110638
Author(s):  
Shingo Morishita ◽  
Toshitaka Yoshii ◽  
Hiroyuki Inose ◽  
Takashi Hirai ◽  
Masato Yuasa ◽  
...  
Keyword(s):  
Cervical Myelopathy ◽  
Cervical Spondylotic Myelopathy ◽  
Perioperative Complications ◽  
Posterior Longitudinal Ligament ◽  
Medical Costs ◽  
Complication Rates ◽  
Systemic Complications ◽  
Hospitalization Costs ◽  
Degenerative Cervical Myelopathy ◽  
Inpatient Database

Study Design Retrospective cohort study. Objectives Laminoplasty (LAMP) is one of the effective methods to successfully achieve surgical decompression in patients with degenerative cervical myelopathy (DCM). However, little evidence exists regarding the perioperative complications in LAMP for patients with ossification of the longitudinal ligament (OPLL) compared with cervical spondylotic myelopathy (CSM). We aimed to investigate the perioperative complication rates and medical costs of DCM, including OPLL and CSM patients who underwent LAMP using a large national inpatient database. Methods This study identified patients who underwent LAMP for OPLL and CSM from 2010 to 2016 using the Japanese Diagnosis Procedure Combination database. We compared the incidence of perioperative complications (systemic and local), reoperation rates, medical costs during hospitalization, and mortality were between the OPLL and CSM groups after propensity score matching. Results This study included 22,714 patients (OPLL: 7485 patients, CSM: 15,229 patients). Consequently, 7169 pairs were matched. More perioperative systemic complications were detected in the OPLL group (one complication: 9.1% vs 7.7%; P = .002), especially for pneumonia (.5% vs .2%; P = .001) and dysphagia (.5% vs .2%; P = .004). The local complication rate was also higher in the OPLL group (paralysis: 1.1% vs .6%, P = .006; spinal fluid leakage: .4% vs .1%, P = .002). The hospitalization costs were approximately $2300 higher ($19,024 vs $16,770; P < .001) in the OPLL group. Conclusions More perioperative complications and higher medical costs were noted in patients with OPLL than in patients with CSM who underwent LAMP.

scholarly journals Decision Tree Analysis on the Factors Influencing the COI of Infantile Bronchopneumonia Inpatients in a Northern Hospital of China

2019 ◽  
Author(s):  
dongmei pei ◽  
YANGYANG YUE ◽  
jiakai guo ◽  
qiyong guo
Keyword(s):  
Decision Tree ◽  
Medical Costs ◽  
Decision Tree Analysis ◽  
Tree Analysis ◽  
Hospitalization Cost ◽  
Factors Influencing ◽  
High Death Rate ◽  
Hospitalization Costs ◽  
High Death ◽  
Healthy Growth

Abstract Background: Bronchopneumonia is a disease with a high death rate for children in developing countries. It not only affects the healthy growth of children, but also puts economic pressure and additional burdens on their families and society. Social development and advancement may change the factors influencing the hospitalization costs. This study aimed to explore reasonable cost control approaches by analyzing the factors related to unreasonable increases in medical costs, so as to standardize the diagnosis and treatment behaviors and determine management methods for scientific medical costs. Methods: Using the decision tree analysis method combined with the characteristic variables of inpatients, data mining and analysis were performed on the assortment of charges for15,980infantile bronchopneumonia inpatients in a northern hospital of China during January 2013 to December 2017. Results: The medical costs of infantile bronchopneumonia inpatients tended to decrease year by year. Various factors influencing the hospitalization costs were sequenced in order of decreasing importance: salvage, complications, admission condition, discharge condition, hospital stay, age and medical payment mode. The hospitalization cost of 623(78.5%) patients with salvage during hospitalization was >RMB 10,000. Hospitalization cost of

scholarly journals Comparison of Cost Effectiveness between Video-Assisted Thoracoscopic Surgery (VATS) and Open Lobectomy: A Retrospective Study

2020 ◽  
Author(s):  
Wei Chen ◽  
Zhanwu Yu ◽  
Yichen Zhang ◽  
Hongxu Liu
Keyword(s):  
Blood Transfusion ◽  
Economic Burden ◽  
Thoracoscopic Surgery ◽  
Clinical Effectiveness ◽  
Lung Infection ◽  
Transfusion Rate ◽  
Vats Lobectomy ◽  
Hospitalization Costs ◽  
Lower Lung ◽  
Open Lobectomy

Abstract Background Lung cancer is highly prevalent in Chinese population. The association of operative approach with economic burden in these patients remains unknown. ObjectivesThis institution-level cohort study aimed to compare the cost-related clinical outcomes and health care costs among patients undergoing video-assisted thoracoscopic surgery (VATS) and open lobectomy, and to investigate the factors associated with the costs. MethodsThis retrospective cohort study included patients who underwent VATS or open lobectomy in a provincial referral cancer center in China in 2018. Clinical effectiveness measures included post-operative blood transfusion, lung infection, and length of stay (LOS). Hospitalization costs were extracted from hospital information system to assess economic burden. ResultsCompared to open lobectomy group, the VATS lobectomy group had a lower blood transfusion rate (1.70% vs. 4.33%, P=0.033), lower lung infection rate (23.77% vs. 40.87%, P<0.001) and shorter post-operative LOS (9.42 ± 3.72 days vs. 10.97 ± 5.81 days, P<0.001). Total hospitalization costs of VATS lobectomy group and open lobectomy were similar: RMB 84,908.72±18,914.87, RMB 81,944.70 ±16,625.20, respectively. VATS approach, lung infection, longer post-operative length of stay, male sex, lung cancer diagnosis, and heart disease were associated with higher total hospitalization costs (P<0.05). ConclusionsVATS lobectomy has a lower post-operative blood transfusion rate, lower lung infection rate, and shorter post-operative LOS than open lobectomy. Future studies are needed to investigate other aspects of clinical effectiveness and the economic burden from a societal perspective.

scholarly journals Do preoperative laboratory tests predict blood transfusion needs in cardiac operations?

1983 ◽  
Vol 85 (4) ◽  
pp. 564-569 ◽  
Author(s):  
Glenn Ramsey ◽  
Dean A. Arvan ◽  
Scott Stewart ◽  
Neil Blumberg
Keyword(s):  
Blood Transfusion ◽  
Laboratory Tests ◽  
Cardiac Operations

scholarly journals Survival and Estimation of Direct Medical Costs of Hospitalized COVID-19 Patients in the Kingdom of Saudi Arabia

2020 ◽  
Vol 17 (20) ◽  
pp. 7458 ◽  
Author(s):  
Anas Khan ◽  
Yazed AlRuthia ◽  
Bander Balkhi ◽  
Sultan Alghadeer ◽  
Mohamad-Hani Temsah ◽  
...  
Keyword(s):  
Saudi Arabia ◽  
Proportional Hazards ◽  
Medical Costs ◽  
Cox Proportional Hazards ◽  
Mechanical Ventilators ◽  
Kingdom Of Saudi Arabia ◽  
General Medical Ward ◽  
Icu Admission ◽  
Direct Medical Costs ◽  
Hospitalization Costs

Objectives: Assess the survival of hospitalized coronavirus disease 2019 (COVID-19) patients across age groups, sex, use of mechanical ventilators (MVs), nationality, and intensive care unit (ICU) admission in the Kingdom of Saudi Arabia. Methods: Data were retrieved from the Saudi Ministry of Health (MoH) between 1 March and 29 May 2020. Kaplan–Meier (KM) analyses and multiple Cox proportional-hazards regression were conducted to assess the survival of hospitalized COVID-19 patients from hospital admission to discharge (censored) or death. Micro-costing was used to estimate the direct medical costs associated with hospitalization per patient. Results: The number of included patients with complete status (discharge or death) was 1422. The overall 14-day survival was 0.699 (95%CI: 0.652–0.741). Older adults (>70 years) (HR = 5.00, 95%CI = 2.83–8.91), patients on MVs (5.39, 3.83–7.64), non-Saudi patients (1.37, 1.01–1.89), and ICU admission (2.09, 1.49–2.93) were associated with a high risk of mortality. The mean cost per patient (in SAR) for those admitted to the general Medical Ward (GMW) and ICU was 42,704.49 ± 29,811.25 and 79,418.30 ± 55,647.69, respectively. Conclusion: The high hospitalization costs for COVID-19 patients represents a significant public health challenge. Efficient allocation of healthcare resources cannot be emphasized enough.

Cost of lung cancer in East Azerbaijan province, in Iran, in 2017

2020 ◽  
Vol 14 (3) ◽  
pp. 461-470
Author(s):  
Habibeh Mir ◽  
Farshad Seyednejad ◽  
Habib Jalilian ◽  
Shirin Nosratnejad ◽  
Mahmood Yousefi
Keyword(s):  
Lung Cancer ◽  
Length Of Hospital Stay ◽  
Indirect Costs ◽  
Medical Costs ◽  
Content Type ◽  
Direct Medical Costs ◽  
Hospitalization Costs ◽  
Illness Study ◽  
East Azerbaijan ◽  
The Cost

Purpose Costs estimation is essential and important to resource allocation and prioritizing different interventions in the health system. The purpose of this paper is to estimate the costs of lung cancer in Iran, in 2017. Design/methodology/approach This was a prevalence-based cost of illness study with a bottom-up approach costing conducted from October 2016 to April 2017. The sample included 645 patients who referred to Imam Reza hospital, Tabriz, Iran, in 2017. Follow-up interviews were every two months. Hospitalization costs extracted from the patient’s record and outpatient costs, nondirect medical costs and indirect costs collected using questionnaire. SPSS software version 22 was used for the data analysis. Findings Mean direct medical costs, nondirect medical costs and indirect costs amounted to 36,637.02 ± 23,515.13 PPP (2016) (251,313,217.83 Rials), 2,025.25 ± 3,303.72 PPP (2016) (16,613,202.53 Rials) and 48,348.55 ± 34,371.84 PPP (2016) (396,599,494.56 Rials), respectively. There was a significant and negative correlation between direct medical costs, direct nonmedical costs, indirect costs and age at diagnosis, and there was a significant and positive correlation between the length of hospital stay and direct medical cost. Originality/value As the cost of lung cancer is substantial and there have been little studies in this area, the objective of this study is to investigate the cost of lung cancer and present ways to tackle this.

Sign in / Sign up

Export Citation Format

Share Document